These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29467191)

  • 1. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
    Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
    Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
    Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
    Pasca S; Chifotides HT; Verstovsek S; Bose P
    Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
    Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
    Int J Lab Hematol; 2024 Aug; 46(4):687-694. PubMed ID: 38665121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
    Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
    Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms.
    Chen D; Weinberg OK
    Int J Lab Hematol; 2023 Dec; 45(6):839-844. PubMed ID: 37867386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
    Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
    Loscocco GG; Rotunno G; Mannelli F; Coltro G; Gesullo F; Pancani F; Signori L; Maccari C; Esposito M; Paoli C; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2024 Jan; 99(1):68-78. PubMed ID: 37846894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted deep sequencing in polycythemia vera and essential thrombocythemia.
    Tefferi A; Lasho TL; Guglielmelli P; Finke CM; Rotunno G; Elala Y; Pacilli A; Hanson CA; Pancrazzi A; Ketterling RP; Mannarelli C; Barraco D; Fanelli T; Pardanani A; Gangat N; Vannucchi AM
    Blood Adv; 2016 Nov; 1(1):21-30. PubMed ID: 29296692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.
    Bartels S; Vogtmann J; Schipper E; Büsche G; Schlue J; Lehmann U; Kreipe H
    Eur J Haematol; 2021 Apr; 106(4):520-528. PubMed ID: 33460496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated and blast phase myeloproliferative neoplasms.
    Saliba AN; Gangat N
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New mutations and pathogenesis of myeloproliferative neoplasms.
    Vainchenker W; Delhommeau F; Constantinescu SN; Bernard OA
    Blood; 2011 Aug; 118(7):1723-35. PubMed ID: 21653328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
    Yogarajah M; Tefferi A
    Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
    Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
    Beer PA; Delhommeau F; LeCouédic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR
    Blood; 2010 Apr; 115(14):2891-900. PubMed ID: 20008300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.
    Brecqueville M; Rey J; Devillier R; Guille A; Gillet R; Adélaide J; Gelsi-Boyer V; Arnoulet C; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D; Murati A
    Haematologica; 2014 Jan; 99(1):37-45. PubMed ID: 23996481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.